Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.

As an aid in the prevention of coccidiosis caused by Eimeria adenoeides, E.gallopavonis, and E.meleagrimitis; for the prevention of bacterial infections caused by Pasteurella multocida (fowl cholera); for the treatment of skin and soft tissue infections. Ormetoprim potentiates the activity of sulfadimethoxine. The in vitro antibacterial spectrum and activity of the 2 compounds are very similar. Sulfonamides competitively inhibit bacterial synthesis of folic acid (pteroylglutamic acid) from paraaminobenzoic acid. Conditions reported following use of sulfonamides or potentiated sulfonamides include polyarthritis, urticaria, facial swelling, fever, hemolytic anemia, polydypsia, polyuria, hepatitis, vomiting, anorexia, diarrhea, and neurologic disorders. In rare instances, neurologic signs including behavioral changes, ataxia, seizures, aggression, and hyperexcitability have been reported. Keratitis sicca, possibly due to prolonged use of sulfonamides, has been reported.

Midecamycin (Acetate) is a macrolide antibiotic with actions and uses similar to those of erythromycin but somewhat less active. It is synthesized from Streptomyces mycarofaciens. It has been given by mouth to treat variety of bacterial infections like respiratory tract, ear, skin infections etc. Antibiotics require constant drug level in body for therapeutic effect. This is achieved by taking the drug at regular interval of time throughout the day and night as prescribed. Midecamycin (Acetate) is primarily indicated in conditions like Bronchitis, Laryngopharyngitis, Otitis media, Periodontitis, Pneumonia, Respiratory tract infections, Skin infections, Subcutaneous abscess, Tonsillitis. Midecamycin inhibits bacterial growth by targeting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. Resistance to midecamycin is commonly attributed to mutations in 50S rRNA preventing midecamycin binding allowing the cell to synthesize proteins free of error.

Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.